全文获取类型
收费全文 | 1662篇 |
免费 | 81篇 |
国内免费 | 3篇 |
专业分类
耳鼻咽喉 | 4篇 |
儿科学 | 67篇 |
妇产科学 | 12篇 |
基础医学 | 172篇 |
口腔科学 | 30篇 |
临床医学 | 117篇 |
内科学 | 550篇 |
皮肤病学 | 48篇 |
神经病学 | 118篇 |
特种医学 | 40篇 |
外科学 | 275篇 |
综合类 | 9篇 |
预防医学 | 55篇 |
眼科学 | 11篇 |
药学 | 69篇 |
中国医学 | 2篇 |
肿瘤学 | 167篇 |
出版年
2023年 | 10篇 |
2022年 | 13篇 |
2021年 | 26篇 |
2020年 | 18篇 |
2019年 | 27篇 |
2018年 | 33篇 |
2017年 | 23篇 |
2016年 | 25篇 |
2015年 | 14篇 |
2014年 | 32篇 |
2013年 | 43篇 |
2012年 | 52篇 |
2011年 | 53篇 |
2010年 | 37篇 |
2009年 | 26篇 |
2008年 | 61篇 |
2007年 | 59篇 |
2006年 | 60篇 |
2005年 | 90篇 |
2004年 | 72篇 |
2003年 | 55篇 |
2002年 | 70篇 |
2001年 | 77篇 |
2000年 | 95篇 |
1999年 | 72篇 |
1998年 | 21篇 |
1997年 | 11篇 |
1996年 | 13篇 |
1995年 | 18篇 |
1994年 | 19篇 |
1993年 | 17篇 |
1992年 | 40篇 |
1991年 | 65篇 |
1990年 | 48篇 |
1989年 | 34篇 |
1988年 | 41篇 |
1987年 | 27篇 |
1986年 | 31篇 |
1985年 | 32篇 |
1984年 | 17篇 |
1983年 | 19篇 |
1979年 | 9篇 |
1978年 | 10篇 |
1975年 | 14篇 |
1974年 | 8篇 |
1973年 | 11篇 |
1971年 | 16篇 |
1970年 | 15篇 |
1969年 | 9篇 |
1966年 | 7篇 |
排序方式: 共有1746条查询结果,搜索用时 15 毫秒
81.
Yasushi Sawayama Hidehiro Itonaga Takuya Fukushima Nobuaki Nakano Hiroshi Fujiwara Atae Utsunomiya Takahiro Fukuda Toshihiro Miyamoto Tetsuya Eto Kaname Miyashita Hirohisa Nakamae Masao Ogata Atsushi Yamanoha Yasuhiko Miyazaki Junya Kanda Yoshiko Atsuta Koji Kato ATL Working Group of the Japan Society for Hematopoietic Cell Transplantation 《American journal of hematology》2019,94(5):E143-E146
82.
83.
Cytomegalovirus (CMV) antigenaemia for rapid diagnosis and monitoring of CMV-associated disease after bone marrow transplantation 总被引:4,自引:0,他引:4
Hisashi Gondo Toshio Minematsu Mine Harada Koichi Akashi Shin Hayashi Shuichi Taniguchi Kazuo Yamasaki Tsunefumi Shibuya Yasushi Takamatsu Takanori Teshima Tetsuya Eto Koji Nagafuji Shin-ichi Mizuno Kenji Hosoda Ryoichi Mori Yoichi Minamishima Yoshiyuki Niho 《British journal of haematology》1994,86(1):130-137
A technique for the rapid detection of cytomegalovirus (CMV) antigen-positive blood leucocytes (CMV antigenaemia) was evaluated in 15 marrow transplant patients as a means of diagnosis and for monitoring CMV-associated disease. CMV antigenaemia was determined by direct immunoperoxidase staining of leucocytes with a peroxidase-labelled monoclonal antibody, HRP-C7, which binds an immediate-early antigen of human CMV.
CMV antigenaemia occurred in 7/15 marrow transplant patients (47%) and was initially detected between 4 and 6 weeks after transplantation. CMV-associated diseases developed in 3/15 patients (20%). All patients with CMV-associated disease had a relatively large number of CMV antigen-positive leucocytes, exceeding 10 per 50000 white blood cells (WBCs). In the remaining 12 patients, CMV antigen-positive leucocytes were less than 10 per 50000 WBCs or were undetectable. CMV-associated disease did not develop in these patients during the period of monitoring. CMV antigen-positive leucocytes were detected more frequently in patients who developed acute graft-versus-host disease (GVHD) or haemorrhagic cystitis than in those without such complications. CMV antigens were detectable from 1 to 4 weeks before the onset of CMV-associated disease which allowed initiation of ganciclovir treatment at an early stage. The degree of CMV antigenaemia paralleled the clinical symptoms and signs, higher degrees of antigenaemia being associated with more significant disease. Thus, the detection of CMV antigen-positive blood leucocytes is useful for the diagnosis and monitoring of CMV-associated disease following bone marrow transplantation. 相似文献
CMV antigenaemia occurred in 7/15 marrow transplant patients (47%) and was initially detected between 4 and 6 weeks after transplantation. CMV-associated diseases developed in 3/15 patients (20%). All patients with CMV-associated disease had a relatively large number of CMV antigen-positive leucocytes, exceeding 10 per 50000 white blood cells (WBCs). In the remaining 12 patients, CMV antigen-positive leucocytes were less than 10 per 50000 WBCs or were undetectable. CMV-associated disease did not develop in these patients during the period of monitoring. CMV antigen-positive leucocytes were detected more frequently in patients who developed acute graft-versus-host disease (GVHD) or haemorrhagic cystitis than in those without such complications. CMV antigens were detectable from 1 to 4 weeks before the onset of CMV-associated disease which allowed initiation of ganciclovir treatment at an early stage. The degree of CMV antigenaemia paralleled the clinical symptoms and signs, higher degrees of antigenaemia being associated with more significant disease. Thus, the detection of CMV antigen-positive blood leucocytes is useful for the diagnosis and monitoring of CMV-associated disease following bone marrow transplantation. 相似文献
84.
Etoh T Kato J Takenaga M Imamura T Kitamura K Koiwaya Y Eto T 《Clinical cardiology》1999,22(2):113-117
BACKGROUND: Adrenomedullin (AM) is a potent vasodilatory peptide discovered in human pheochromocytoma tissue. Proadrenomedullin N-terminal 20 peptide (PAMP) processed from an AM precursor is also a novel hypotensive peptide which inhibits catecholamine secretion from sympathetic nerve endings. HYPOTHESIS: The present study sought to examine the relationships between the two peptides and other clinical parameters by measuring the plasma AM and PAMP concentrations in 98 patients with heart failure. METHODS: In all, 98 patients [65 men and 33 women, aged 58.2 +/- 11.0 years, mean +/- standard deviation (SD)] with heart failure and 26 healthy volunteers (12 men and 14 women, aged 54.1 +/- 8.6 years) were examined in this study. Heart failure was secondary to previous myocardial infarction in 58 patients, valvular disease in 28, cardiomyopathy in 9, and congenital heart disease in 3. All patients were classified into two groups of class I or II (Group 1) and class III or IV (Group 2) according to the New York Heart Association (NYHA) functional classification. RESULTS: Both plasma AM and PAMP concentrations in the patients were significantly higher than those in healthy volunteers. In addition, plasma AM and PAMP concentrations in patients in class III or IV of New York Heart Association (NYHA) classification were significantly higher than those in NYHA class I or II. The elevated plasma concentrations of these peptides in patients in NYHA class III or IV significantly decreased in response to the treatment for 7 days. There was a significant correlation between plasma AM and PAMP, though the plasma concentration of PAMP was one-fifth to one-seventh of that of AM in patients and controls. The plasma AM concentration correlated significantly with the plasma concentrations of atrial and brain natriuretic peptides, epinephrine, and right atrial pressure, whereas such a relationship was not noted for the plasma PAMP concentration. CONCLUSIONS: Judging from the difference in not only the biological actions but also the hormonal profiles between AM and PAMP, they may differentially modulate the cardiovascular system in patients with heart failure, although they are processed from the same precursor. 相似文献
85.
Additive combination of actarit and methotrexate in the treatment of refractory rheumatoid arthritis
M. Aso Y. Tanaka K. Saito K. Fujii A. Takazawa T. Ota S. Eto 《Modern rheumatology / the Japan Rheumatism Association》2000,10(2):103-109
The objective of this study was to evaluate the efficacy and safety of an additive combination of a disease-modifying antirheumatic
drug (DMARD) actarit and low-dose methotrexate (MTX) in patients with active rheumatoid arthritis (RA) unresponsive to MTX.
Thirty-four patients with active RA, who had been unsuccessfully treated with MTX for at least 3 months were enrolled on a
24-week course of actarit (300 mg/day) and MTX (2.5–10 mg/week). Disease activity was evaluated by physical global assessments
using conventional measures (Japan Rheumatism Association), and the American College of Rheumatology (ACR) criteria of improvements
in RA. Thirty-two patients completed this study. No severe adverse drug reactions were seen. Patients whose RA did not respond
to MTX alone responded to the combination therapy, with a significant improvement in the duration of morning stiffness, grip
strength, swollen joint counts, patient's articular pain score, modified health assessment questionnaire (M-HAQ) score, score
of both patient's and physician's global assessments, and C-reactive proteins (CRP). Sixteen patients (50.0%) and 9 patients
(31.0%) showed a significant improvement in overall conventional measures, and ACR response criteria, respectively, and 60.0%
of RA patients who received MTX for more than 1 year showed improvement in ACR definition. Patients who responded to the combination
treatment within the first 12 weeks showed persistent improvement for the remaining part of the 24 week period. Our results
indicate that the additive combination of actarit and MTX is safe, and without serious adverse effects, and has an excellent
efficacy in patients with active and refractory RA.
Received: July 28, 1999 / Accepted: January 28, 2000 相似文献
86.
Kamezaki K Kikushige Y Numata A Miyamoto T Takase K Henzan H Aoki K Kato K Nonami A Kamimura T Arima F Takenaka K Harada N Fukuda T Hayashi S Ohno Y Eto T Harada M Nagafuji K 《Bone marrow transplantation》2007,39(9):523-527
To investigate effects of the preautografting administration of rituximab on the mobilization and engraftment of peripheral blood stem cells (PBSC), we retrospectively analyzed the outcomes of 43 newly diagnosed diffuse-large B-cell lymphoma patients who received CHOP chemotherapy with or without rituximab as a first-line treatment before autologous PBSC transplantation (PBSCT). There was no difference in the number of CD34(+) cells among PBSC between the non-rituximab and the rituximab groups. Although B-cells were completely depleted from PBSC in the rituximab group, we found no difference in the expression of CXCR-4, VLA-4 and c-Kit on PBSC, indicating that rituximab did not affect the expression of these adhesion molecules, which might be involved in the mechanism of mobilization. There was no significant difference in the recovery of neutrophils and platelets, transplant-related toxicity and post-transplant complications between the two groups. Despite the short follow-up, there was no significant difference in progression-free survival between the two groups. These results indicated no adverse effect of rituximab on the mobilization and engraftment of PBSC. Larger studies are required to determine the impact of rituximab on the mobilization and function of PBSC as well as whether a survival advantage exists in patients who undergo auto-PBSCT with rituximab. 相似文献
87.
Overexpression of matrix metalloproteinase-9 promotes intravascular thrombus formation in porcine coronary arteries in vivo 总被引:13,自引:0,他引:13
Morishige K Shimokawa H Matsumoto Y Eto Y Uwatoku T Abe K Sueishi K Takeshita A 《Cardiovascular research》2003,57(2):572-585
OBJECTIVE: Matrix metalloproteinases (MMPs) cause extracellular matrix degradation and may be involved in the rupture of atherosclerotic plaques by degrading fibrous cap, resulting in the intravascular thrombus formation. Here we examined whether local overexpression of MMP-9 alters the characteristics of arteriosclerotic vascular lesions and promotes thrombosis after balloon injury in porcine coronary arteries in vivo. METHODS AND RESULTS: Balloon angioplasty was performed in the left coronary arteries followed by injection of adenovirus vector solution encoding either MMP-9 or beta-galactosidase (beta-gal) gene into the injured coronary arteries. Three weeks after the gene transfer, histological examination demonstrated that macroscopic intravascular thrombus formation was noted at the MMP-9-transfected site but not at the beta-gal-transfected site. Microscopic intramural thrombus area was significantly larger at the MMP-9-transfected site as compared to the beta-gal-transfected site. Co-transfection of tissue inhibitor of metalloproteinase-1 (TIMP-1) with MMP-9 prevented the intravascular thrombus formation in vivo. Western blot analysis revealed the reduced expression of intact tissue factor pathway inhibitor-1 and the increased tissue factor (TF) expression at the MMP-9-transfected sites. CONCLUSION: These results provide the first in vivo evidence that overexpression of MMP-9 promotes intravascular thrombus formation after balloon injury due in part to the activation of TF-mediated coagulation cascade. 相似文献
88.
89.
90.
Masatoshi Eto Masahiko Harano Katsunori Tatsugami Mamoru Harada Yoriyuki Kamiryo Keijiro Kiyoshima Masumitsu Hamaguchi Masazumi Tsuneyoshi Yasunobu Yoshikai Seiji Naito 《Clinical cancer research》2007,13(3):1029-1035
PURPOSE: Much attention has been paid to nonmyeloablative allogeneic stem cell transplantation for the treatment of renal cancer. We recently proposed a cyclophosphamide-using nonmyeloablative cell therapy in which donor lymphocyte infusion (DLI) was carried out after the tolerance induction to donor cells. In considering the clinical application of the cyclophosphamide-using cell therapy, attempts to reduce graft-versus-host disease (GVHD) are crucial. The aim of the present study was to modify the cyclophosphamide-using cell therapy to reduce the risk of GVHD while preserving the antitumor activity against renal cancer. EXPERIMENTAL DESIGN: We assessed whether a delay in performing DLI from day 1 to day 5 after the cyclophosphamide treatment could reduce the risk of GVHD while preserving antitumor activity against RENCA, a murine carcinogen-induced renal cell carcinoma, in the cyclophosphamide-using cell therapy. RESULTS: Regarding the in vivo antitumor effect, there was no difference between DLI on day 1 and day 5 after the cyclophosphamide treatment, whereas the histologic findings of the small intestine showed that the cyclophosphamide-using cell therapy with DLI on day 5 decreased the risk of GVHD. In addition, the acquired immunity against RENCA was also observed in the RENCA-rejected mice that had been treated with DLI on day 5. CONCLUSIONS: Our results show that a delay in DLI during cyclophosphamide-using nonmyeloablative cell therapy can dissociate graft-versus-tumor effects from GVHD by reducing the risk of GVHD. 相似文献